



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite  
501, Pleasanton, CA 94588,  
USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:**  
bpgoffice@wjgnet.com

March,15 2018

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 38401-revision.doc).

**Title:** Achievable complete remission of advanced non-small-cell lung cancer: case report

**Author:** Ning-Ning Yang, Fei Xiong, Qing He, Yong-Song Guan

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 38401

**The manuscript has been improved according to the suggestions of reviewers:**

**1 Format has been updated.**

**2 Revision has been made according to the suggestions of the reviewer.**

**Reviewer 1**

1) Is icotinib an approved drug in first line therapy of NSCLC?

Icotinib has been approved as the first-line therapy in patients with advanced NSCLC with sensitive mutation on February 22, 2011, by China Food and Drug Administration, and related information is added in the manuscript.

2) Is BAI an approved treatment in NSCLC?

Intra-arterial infusion chemotherapy is an approved treatment for NSCLC in China and Japan. It has been introduced to medical treatment of tumors for more than 50 years, and it has the potential to reduce the tumor size and to relieve symptoms, with low toxicity and good repeatability. It is especially suitable for the patients with advanced lung cancer who are intolerable to systemic chemotherapy or radiotherapy. It has been proved that, among the feeding arteries of lung cancer, bronchial arteries showed the best response to BAI.

3) Was the response assessed by RECIST criteria or any other criteria?

The response is assessed by RECIST 1.1 criteria, and related information is added to the manuscript.

4) Was PET scan considered for Evaluation?

PET/CT had been considered for evaluation. However, the patient was unwilling to use PET/CT because of economic reason. So we used contrast enhanced chest CT and abdominal ultrasound, which are completely covered



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite  
501, Pleasanton, CA 94588,  
USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:**  
bpgoffice@wjgnet.com

by medical insurance and can be repeatedly used.

5) Was surgery considered after first initial significant response?

The patient was not a surgical candidate because of his poor lung function after first initial significant response. Now, minimally invasive surgery is recommended for the patient's consideration.

6) Was there any toxicity to EGFR Targeted therapy?

The most common side-effects of EGFR TKIs are diarrhoea, acneiform skin rash, and paronychia, and none of them occurred in this patient.

7) Was the patient a smoker?

The patient is a non-smoker, and this information is added to the manuscript.

#### **Reviewer 2**

Dear Author, Well written.. I think it is suitable for publication Best wishes....

Thank you very much for your positive comment.

Thank you again for publishing our manuscript in the World Journal of Clinical Cases.

Sincerely yours,

**Yong-Song Guan**

Yong-Song Guan, MD, PhD  
Department of Oncology  
West China Hospital of Sichuan University  
Sichuan Province  
Chengdu 610041, China  
Fax: +86-28-85423278  
E-mail: yongsongguan@yahoo.com